Percutaneous renal sympathetic denervation – new perspective in resistant hypertension Review article
Article Sidebar
Main Article Content
Abstract
Percutaneous cardiovascular interventions have been recently enhanced by a new therapeutic option which is catheter-based renal denervation. This new therapeutic option reduces renal sympathetic nervous activation and leads to sustained blood pressure reduction. The use of radiofrequency ablation reduced the invasiveness of the procedure. This very promising, minimally invasive treatment, may be a real alternative to drug therapy, especially in cases of resistant hypertension. There are convincing data on patients with resistant hypertension and promising perspectives in primary hypertension. Renal sympathetic denervation could also be an attractive future strategy for other diseases, where the activation of the sympathetic nervous system plays an important pathophysiological role; such as in sleep apnea syndrome, heart failure and chronic kidney disease.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. DiBona G.F.: Functionally specific renal sympathetic nerve fibers: role in cardiovascular regulation. Am. J. Hypertens. 2001; 14: 163S-170S.
3. Smithwick R.H., Thompson J.E.: Splanchnicectomy for essential hypertension; results in 1,266 cases. J. Am. Med. Assoc. 1953; 152: 1501-1504.
4. Allen E.V.: Sympathectomy for essential hypertension. Circulation 1952; 6: 131-40.
5. Smithwick R.H.: Sympathectomy, splanchniecoctomy and vagotomy. Rev. Surg. 1973; 30: 153-73.
6. Schlaich M.P., Sobotka P.A., Krum H. et al.: Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 2009; 361: 932-934.
7. Krum H., Schlaich M., Whitbourn R. et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
8. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011 May; 57(5): 911-7.
9. Symplicity, HTN-2 Investigators; Esler M.D., Krum H. et al.: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
10. Czernichow S., Zanchetti A., Turnbull F. et al.: Blood Pressure Lowering Treatment Trialists’ Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J. Hypertens. 2011; 29: 4-16.